Phase 2 efficacy studies are scheduled for the first half of 2025, moving the treatment closer to market availability.

The Dutch device firm is touting the results of its sleep diagnostic trials finding its sleep device comparable with in-lab tests.

For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...

Cancer Research UK provided the funding for the study, which saw participation from UCL, UCLH and Francis Crick Institute.

Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

And yet, data science is now poised to usher in a level and acceleration of progress that even life sciences have never ...

Over the holidays, many people may have chosen to welcome a new puppy into their families. While those big eyes and wiggly tails may be irresistible, these families may quickly ...

ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector ® to ...

Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce that it has begun human testing on its latest barium contrast suite of products (as ...

Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available for ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...